Melagatran (BioDeep_00000014106)

   


代谢物信息卡片


SCHEMBL8083301

化学式: C22H31N5O4 (429.2376)
中文名称: 美拉加群
谱图信息: 最多检出来源 Homo sapiens(plant) 12.04%

分子结构信息

SMILES: C1CCC(CC1)C(C(=O)N2CCC2C(=O)NCC3=CC=C(C=C3)C(=N)N)NCC(=O)O
InChI: InChI=1S/C22H31N5O4/c23-20(24)16-8-6-14(7-9-16)12-26-21(30)17-10-11-27(17)22(31)19(25-13-18(28)29)15-4-2-1-3-5-15/h6-9,15,17,19,25H,1-5,10-13H2,(H3,23,24)(H,26,30)(H,28,29)/t17-,19+/m0/s1

描述信息

B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AE - Direct thrombin inhibitors
C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent > C173066 - Direct Thrombin Inhibitor
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015842 - Serine Proteinase Inhibitors
D006401 - Hematologic Agents > D000925 - Anticoagulants > D000991 - Antithrombins

同义名列表

2 个代谢物同义名

Melagatran; SCHEMBL8083301



数据库引用编号

10 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表


文献列表

  • Yoshiyuki Morishima, Chikako Kamisato, Yuko Honda. Prolongation of clot lysis time by a direct thrombin inhibitor melagatran mediated by paradoxical enhancement of thrombin generation: comparison with a direct factor Xa inhibitor edoxaban. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2021 Apr; 32(3):209-215. doi: 10.1097/mbc.0000000000001020. [PMID: 33560005]
  • Chikako Kamisato, Taketoshi Furugohri, Yoshiyuki Morishima. A direct thrombin inhibitor suppresses protein C activation and factor Va degradation in human plasma: Possible mechanisms of paradoxical enhancement of thrombin generation. Thrombosis research. 2016 May; 141(?):77-83. doi: 10.1016/j.thromres.2016.03.005. [PMID: 26974491]
  • Taketoshi Furugohri, Yoshiyuki Morishima. Paradoxical enhancement of the intrinsic pathway-induced thrombin generation in human plasma by melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, or heparin. Thrombosis research. 2015 Sep; 136(3):658-62. doi: 10.1016/j.thromres.2015.06.034. [PMID: 26188924]
  • Silke Haerteis, Annabel Krappitz, Matteus Krappitz, Jane E Murphy, Marko Bertog, Bettina Krueger, Regina Nacken, Hyunjae Chung, Morley D Hollenberg, Wolfgang Knecht, Nigel W Bunnett, Christoph Korbmacher. Proteolytic activation of the human epithelial sodium channel by trypsin IV and trypsin I involves distinct cleavage sites. The Journal of biological chemistry. 2014 Jul; 289(27):19067-78. doi: 10.1074/jbc.m113.538470. [PMID: 24841206]
  • E Perzborn, S Heitmeier, U Buetehorn, V Laux. Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo. Journal of thrombosis and haemostasis : JTH. 2014 Jul; 12(7):1054-65. doi: 10.1111/jth.12591. [PMID: 24766850]
  • Hee Dong Park, Sung-Hack Lee, Tae Hoon Kim, Sun Hwa Lee, Kwan Hyung Cho, Aeri Kim. Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug. Bioorganic & medicinal chemistry letters. 2013 Sep; 23(17):4779-84. doi: 10.1016/j.bmcl.2013.07.008. [PMID: 23899618]
  • Saartje Bloemen, H Coenraad Hemker, Raed Al Dieri. Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation. Haematologica. 2013 Apr; 98(4):549-54. doi: 10.3324/haematol.2012.073601. [PMID: 23100275]
  • Taketoshi Furugohri, Toshio Fukuda, Naoki Tsuji, Akemi Kita, Yoshiyuki Morishima, Toshiro Shibano. Melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, nor heparin aggravates tissue factor-induced hypercoagulation in rats. European journal of pharmacology. 2012 Jul; 686(1-3):74-80. doi: 10.1016/j.ejphar.2012.04.031. [PMID: 22546231]
  • Eugene P Ceppa, Victoria Lyo, Eileen F Grady, Wolfgang Knecht, Sarah Grahn, Anders Peterson, Nigel W Bunnett, Kimberly S Kirkwood, Fiore Cattaruzza. Serine proteases mediate inflammatory pain in acute pancreatitis. American journal of physiology. Gastrointestinal and liver physiology. 2011 Jun; 300(6):G1033-42. doi: 10.1152/ajpgi.00305.2010. [PMID: 21436316]
  • Masaki Kawamura, Noriko Konishi, Katsuhiko Hiroe, Ken-ichi Shofuda, Yasuhiro Imaeda, Takuya Fujimoto, Keiji Kubo. Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis. Journal of cardiovascular pharmacology. 2010 Aug; 56(2):156-61. doi: 10.1097/fjc.0b013e3181e2bfcf. [PMID: 20410831]
  • F Favreau, R Thuillier, J Cau, S Milin, E Manguy, G Mauco, X Zhu, L O Lerman, T Hauet. Anti-thrombin therapy during warm ischemia and cold preservation prevents chronic kidney graft fibrosis in a DCD model. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2010 Jan; 10(1):30-9. doi: 10.1111/j.1600-6143.2009.02924.x. [PMID: 19958330]
  • Manthena V S Varma, Bo Feng, R Scott Obach, Matthew D Troutman, Jonathan Chupka, Howard R Miller, Ayman El-Kattan. Physicochemical determinants of human renal clearance. Journal of medicinal chemistry. 2009 Aug; 52(15):4844-52. doi: 10.1021/jm900403j. [PMID: 19445515]
  • Sebastien Giraud, Raphael Thuillier, Aude Belliard, William Hebrard, Cédric Nadeau, Serge Milin, Jean-Michel Goujon, Emilie Manguy, Gérard Mauco, Thierry Hauet, Laurent Macchi. Direct thrombin inhibitor prevents delayed graft function in a porcine model of renal transplantation. Transplantation. 2009 Jun; 87(11):1636-44. doi: 10.1097/tp.0b013e3181a5b154. [PMID: 19502954]
  • R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals. 2008 Jul; 36(7):1385-405. doi: 10.1124/dmd.108.020479. [PMID: 18426954]
  • Fabrizio Semeraro, Donatella Piro, Maria R Rossiello, Tiziana Ammollo, Mario Colucci. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots. Thrombosis and haemostasis. 2007 Dec; 98(6):1208-14. doi: 10.1160/th07-05-0375. [PMID: 18064315]
  • Jess L Thompson, Chad E Hamner, D Dean Potter, Matthew Lewin, Thoralf M Sundt, Hartzell V Schaff. Melagatran for thromboprophylaxis after mechanical valve implantation: results in a heterotopic porcine model. The Journal of thoracic and cardiovascular surgery. 2007 Aug; 134(2):359-65. doi: 10.1016/j.jtcvs.2007.01.093. [PMID: 17662773]
  • Nicoletta Nitescu, Elisabeth Grimberg, Sven-Erik Ricksten, Niels Marcussen, Gregor Guron. Thrombin inhibition with melagatran does not attenuate renal ischaemia-reperfusion injury in rats. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2007 Aug; 22(8):2149-55. doi: 10.1093/ndt/gfm158. [PMID: 17405786]
  • Gerhard Cvirn, Christina Cimenti, Joerg Kutschera, Ulrika Ferstl, Thomas Wagner, Wolfgang Muntean, Gunther Jurgens, Siegfried Gallistl, Martin Koestenberger. Anticoagulant action of melagatran: a comparison between neonates and adults using calibrated automated thrombography (CAT). European journal of pediatrics. 2007 May; 166(5):427-31. doi: 10.1007/s00431-006-0253-6. [PMID: 17047995]
  • Nicoletta Nitescu, Elisabeth Grimberg, Sven-Erik Ricksten, Niels Marcussen, Hans Nordlinder, Gregor Guron. Effects of thrombin inhibition with melagatran on renal hemodynamics and function and liver integrity during early endotoxemia. American journal of physiology. Regulatory, integrative and comparative physiology. 2007 Mar; 292(3):R1117-24. doi: 10.1152/ajpregu.00471.2006. [PMID: 17068159]
  • Boris Leithäuser, Monika Fassbender, Monika Eickhoff, Margareta Elg, Gerrit Eichner, Fritz Reinhard Matthias. The direct thrombin inhibitor melagatran counteracts endotoxin-induced endothelial leukocyte adherence and microvascular leakage in the rat mesentery. Rationale for the treatment of inflammatory disorders beyond sepsis?. Clinical hemorheology and microcirculation. 2007; 36(4):277-89. doi: NULL. [PMID: 17502698]
  • Christina Cimenti, Martin Koestenberger, Bettina Leschnik, Harald Haidl, Wolfgang Muntean. The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT. Thrombosis research. 2007; 119(3):361-7. doi: 10.1016/j.thromres.2006.03.004. [PMID: 16712904]
  • Martin Koestenberger, Siegfried Gallistl, Leschnik Bettina, Christina Cimenti, Joerg Kutschera, Gerhard Cvirn. Effects of melagatran on activated partial thromboplastin time and on ecarin clotting time in cord versus adult plasma. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2006 Nov; 17(8):677-80. doi: 10.1097/01.mbc.0000252604.63142.e0. [PMID: 17102656]
  • Benny Sørensen, Jørgen Ingerslev. A direct thrombin inhibitor studied by dynamic whole blood clot formation. Haemostatic response to ex-vivo addition of recombinant factor VIIa or activated prothrombin complex concentrate. Thrombosis and haemostasis. 2006 Oct; 96(4):446-53. doi: 10.1160/th06-04-0205. [PMID: 17003921]
  • Stefan Kuhle, Alice Lau, Laszlo Bajzar, Patsy Vegh, Jacqueline Halton, Irene Cherrick, Ron Anderson, Sunil Desai, Patricia McCusker, John Wu, Thomas Abshire, Donald Mahoney, Lesley Mitchell. Comparison of the anticoagulant effect of a direct thrombin inhibitor and a low molecular weight heparin in an acquired antithrombin deficiency in children with acute lymphoblastic leukaemia treated with L-asparaginase: an in vitro study. British journal of haematology. 2006 Sep; 134(5):526-31. doi: 10.1111/j.1365-2141.2006.06209.x. [PMID: 16856890]
  • Udo E W Lange, Dorit Baucke, Wilfried Hornberger, Helmut Mack, Werner Seitz, H Wolfgang Höffken. Orally active thrombin inhibitors. Part 2: optimization of the P2-moiety. Bioorganic & medicinal chemistry letters. 2006 May; 16(10):2648-53. doi: 10.1016/j.bmcl.2006.01.046. [PMID: 16460939]
  • Linda C Wernevik, Per Nyström, Magnus Andersson, Gillis Johnsson, Anders Bylock, Takashi Nakanishi, Ulf G Eriksson. Comparable pharmacokinetics and pharmacodynamics of melagatran in Japanese and caucasian volunteers after oral administration of the direct thrombin inhibitor ximelagatran. Clinical pharmacokinetics. 2006; 45(1):85-94. doi: 10.2165/00003088-200645010-00006. [PMID: 16430313]
  • Shir-Jing Ho, Tim A Brighton. Ximelagatran: direct thrombin inhibitor. Vascular health and risk management. 2006; 2(1):49-58. doi: 10.2147/vhrm.2006.2.1.49. [PMID: 17319469]
  • Sofie Bååthe, Bengt Hamrén, Mats O Karlsson, Maria Wollbratt, Margaretha Grind, Ulf G Eriksson. Population pharmacokinetics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in atrial fibrillation patients receiving long-term anticoagulation therapy. Clinical pharmacokinetics. 2006; 45(8):803-19. doi: 10.2165/00003088-200645080-00004. [PMID: 16884319]
  • Theodore E Warkentin, Andreas Greinacher, Sharon Craven, Lori Dewar, Jo-Ann I Sheppard, Frederick A Ofosu. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. Thrombosis and haemostasis. 2005 Nov; 94(5):958-64. doi: 10.1160/th05-03-0154. [PMID: 16363236]
  • C Christersson, J Oldgren, A Bylock, L Wallentin, A Siegbahn. Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction. Journal of thrombosis and haemostasis : JTH. 2005 Oct; 3(10):2245-53. doi: 10.1111/j.1538-7836.2005.01557.x. [PMID: 16194202]
  • Per-Ola Attman, Pia Ottosson, Ola Samuelsson, Ulf G Eriksson, Maria Eriksson-Lepkowska, Gunnar Fager. Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2005 Sep; 20(9):1889-97. doi: 10.1093/ndt/gfh915. [PMID: 15928099]
  • Michael Wolzt, Troy S Sarich, Ulf G Eriksson. Low potential for interactions between melagatran/ximelagatran and other drugs, food, or alcohol. Seminars in vascular medicine. 2005 Aug; 5(3):254-8. doi: 10.1055/s-2005-916164. [PMID: 16123912]
  • Michael Wolzt, Troy S Sarich, Ulf G Eriksson. Pharmacokinetics and pharmacodynamics of ximelagatran. Seminars in vascular medicine. 2005 Aug; 5(3):245-53. doi: 10.1055/s-2005-916163. [PMID: 16123911]
  • Tivadar Fenyvesi, Job Harenberg, Christel Weiss, Ingrid Jörg. Comparison of two different ecarin clotting time methods. Journal of thrombosis and thrombolysis. 2005 Aug; 20(1):51-6. doi: 10.1007/s11239-005-2925-x. [PMID: 16133897]
  • Martin Koestenberger, Siegfried Gallistl, Wolfgang Muntean, Bettina Leschnik, Peter Fritsch, Gerhard Cvirn. Additive effects of anticoagulants: recombinant human activated protein C and heparin or melagatran, in tissue factor-activated umbilical-cord plasma. Thrombosis and haemostasis. 2005 Jul; 94(1):69-74. doi: 10.1160/th05-01-0041. [PMID: 16113786]
  • Martin Koestenberger, Gerhard Cvirn, Siegfried Gallistl, Joerg Kutschera, Wolfgang Muntean. Recombinant human activated protein C, heparin and melagatran in umbilical cord versus adult plasma. Acta paediatrica (Oslo, Norway : 1992). 2005 Jul; 94(7):884-9. doi: 10.1111/j.1651-2227.2005.tb02006.x. [PMID: 16188810]
  • Stefan Carlsson, Margareta Elg. The effects of ximelagatran and warfarin on the prophylaxis of a caval vein thrombosis and bleeding in the anaesthetized rat. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2005 Jun; 16(4):245-9. doi: 10.1097/01.mbc.0000169216.70184.8d. [PMID: 15870543]
  • Taketoshi Furugohri, Yoko Shiozaki, Sumie Muramatsu, Yuko Honda, Chikako Matsumoto, Koji Isobe, Nobutoshi Sugiyama. Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models. European journal of pharmacology. 2005 May; 514(1):35-42. doi: 10.1016/j.ejphar.2005.03.009. [PMID: 15878322]
  • M Hellgren, S Johansson, U G Eriksson, K Wåhlander. The oral direct thrombin inhibitor, ximelagatran, an alternative for anticoagulant treatment during the puerperium and lactation. BJOG : an international journal of obstetrics and gynaecology. 2005 May; 112(5):579-83. doi: 10.1111/j.1471-0528.2004.00494.x. [PMID: 15842280]
  • Martin Koestenberger, Siegfried Gallistl, Gerhard Cvirn, Katrin Baier, Bettina Leschnik, Wolfgang Muntean. Anticoagulant action of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in umbilical cord and adult plasma: an in vitro examination. Thrombosis research. 2005; 115(1-2):135-42. doi: 10.1016/j.thromres.2004.07.003. [PMID: 15567465]
  • Palle Petersen. Ximelagatran--a promising new drug in thromboembolic disorders. Current pharmaceutical design. 2005; 11(4):527-38. doi: 10.2174/1381612053382016. [PMID: 15725069]
  • Timothy A Brighton. The direct thrombin inhibitor melagatran/ximelagatran. The Medical journal of Australia. 2004 Oct; 181(8):432-7. doi: 10.5694/j.1326-5377.2004.tb06367.x. [PMID: 15487959]
  • Martin Koestenberger, Gerhard Cvirn, Siegfried Gallistl, Wolfgang Muntean. Drotrecogin alfa activated (recombinant human activated protein C) in combination with heparin or melagatran: effects on prothrombin time and activated partial thromboplastin time. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2004 Oct; 15(8):693-7. doi: 10.1097/00001721-200412000-00010. [PMID: 15613925]
  • Anne-Louise Hemdahl, Erling Falk, Peter Thorén, Göran K Hansson. Thrombin inhibitor reduces myocardial infarction in apoE-/- x LDLR-/- mice. American journal of physiology. Heart and circulatory physiology. 2004 Aug; 287(2):H872-7. doi: 10.1152/ajpheart.01083.2003. [PMID: 15031124]
  • Martin Koestenberger, Gerhard Cvirn, Siegfried Gallistl, Katrin Baier, Bettina Leschnik, Wolfgang Muntean. Drotrecogin alfa (activated, Xigris) in combination with heparin or melagatran: an in vitro investigation. Journal of thrombosis and thrombolysis. 2004 Aug; 18(1):5-10. doi: 10.1007/s11239-004-0167-y. [PMID: 15744547]
  • Troy C Sarich, Kajs-Marie Schützer, Maria Wollbratt, Ulrika Wall, Eva Kessler, Ulf G Eriksson. No pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers. Journal of clinical pharmacology. 2004 Aug; 44(8):935-41. doi: 10.1177/0091270004268048. [PMID: 15286098]
  • Troy C Sarich, Kajs-Marie Schützer, Hassan Dorani, Ulrika Wall, Inge Kalies, Lis Ohlsson, Ulf G Eriksson. No pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran. Journal of clinical pharmacology. 2004 Aug; 44(8):928-34. doi: 10.1177/0091270004268047. [PMID: 15286097]
  • Michael Wolzt, Marcel Levi, Troy C Sarich, Stig L Boström, Ulf G Eriksson, Maria Eriksson-Lepkowska, Mia Svensson, Jeffrey I Weitz, Margareta Elg, Karin Wåhlander. Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers. Thrombosis and haemostasis. 2004 Jun; 91(6):1090-6. doi: 10.1160/th03-09-0605. [PMID: 15175794]
  • Martin Koestenberger, Siegfried Gallistl, Gerhard Cvirn, Birgit Roschitz, Thomas Rehak, Bettina Leschnik, Wolfgang Muntean. Combined effects of melagatran and eptifibatide on platelet aggregation inhibition but not thrombin generation inhibition. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2004 Mar; 15(2):131-7. doi: 10.1097/00001721-200403000-00004. [PMID: 15091000]
  • G Pindur, S Ziegeler, S Kleinschmidt. [Melagatran and ximelagatran. Pharmacologic characteristics and anesthesiological aspects]. Der Anaesthesist. 2003 Dec; 52(12):1171-5. doi: 10.1007/s00101-003-0602-z. [PMID: 14691631]
  • Susanne Johansson, Karin Wåhlander, Göran Larson, Lis Ohlsson, Marita Larsson, Ulf G Eriksson. Pharmacokinetics and anticoagulant effect of the direct thrombin inhibitor melagatran following subcutaneous administration to healthy young men. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2003 Oct; 14(7):677-84. doi: 10.1097/00001721-200310000-00010. [PMID: 14517494]
  • Michael Wolzt, Maria Wollbratt, Mia Svensson, Karin Wåhlander, Margaretha Grind, Ulf G Eriksson. Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects. European journal of clinical pharmacology. 2003 Oct; 59(7):537-43. doi: 10.1007/s00228-003-0667-2. [PMID: 12955372]
  • D Gustafsson. Oral direct thrombin inhibitors in clinical development. Journal of internal medicine. 2003 Oct; 254(4):322-34. doi: 10.1046/j.1365-2796.2003.01225.x. [PMID: 12974871]
  • Byoung-Hyoun Kim, Sun Young Park, Nak Hee Choi, Jong Hoa Ok. Determination of melagatran in rabbit plasma by high-performance liquid chromatography with automated column switching. Biomedical chromatography : BMC. 2003 Sep; 17(6):373-5. doi: 10.1002/bmc.242. [PMID: 13680847]
  • Gunnar Fager, Marie Cullberg, Maria Eriksson-Lepkowska, Lars Frison, Ulf G Eriksson. Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid. European journal of clinical pharmacology. 2003 Aug; 59(4):283-9. doi: 10.1007/s00228-003-0619-x. [PMID: 12845508]
  • Stig L Boström, Göran F Hansson, Magnus Kjaer, Troy C Sarich. Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2003 Jul; 14(5):457-62. doi: 10.1097/00001721-200307000-00005. [PMID: 12851531]
  • Ulf G Eriksson, Ulf Bredberg, Kristina Gislén, Linda C Johansson, Lars Frison, Martin Ahnoff, David Gustafsson. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. European journal of clinical pharmacology. 2003 May; 59(1):35-43. doi: 10.1007/s00228-003-0565-7. [PMID: 12743672]
  • Bernd Clement, Katrin Lopian. Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug. Drug metabolism and disposition: the biological fate of chemicals. 2003 May; 31(5):645-51. doi: 10.1124/dmd.31.5.645. [PMID: 12695354]
  • Rikard Linder, Siw Frebelius, Katarina Jansson, Jesper Swedenborg. Inhibition of endothelial cell-mediated generation of activated protein C by direct and antithrombin-dependent thrombin inhibitors. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2003 Feb; 14(2):139-46. doi: 10.1097/00001721-200302000-00004. [PMID: 12632023]
  • Marita Larsson, Martin Ahnoff, Anna Abrahamsson, Ulrika Logren, Christina Fakt, Irene Ohrman, Bengt Arne Persson. Determination of ximelagatran, an oral direct thrombin inhibitor, its active metabolite melagatran, and the intermediate metabolites, in biological samples by liquid chromatography-mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2003 Jan; 783(2):335-47. doi: 10.1016/s1570-0232(02)00768-7. [PMID: 12482476]
  • Linda C Johansson, Magnus Andersson, Gunnar Fager, David Gustafsson, Ulf G Eriksson. No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers. Clinical pharmacokinetics. 2003; 42(5):475-84. doi: 10.2165/00003088-200342050-00005. [PMID: 12739985]
  • Ulf G Eriksson, Jaap W Mandema, Mats O Karlsson, Lars Frison, Per Olsson Gisleskog, Ulrika Wählby, Bengt Hamrén, David Gustafsson, Bengt I Eriksson. Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis. Clinical pharmacokinetics. 2003; 42(7):687-701. doi: 10.2165/00003088-200342070-00006. [PMID: 12844328]
  • Ulf G Eriksson, Susanne Johansson, Per-Ola Attman, Henrik Mulec, Lars Frison, Gunnar Fager, Ola Samuelsson. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran. Clinical pharmacokinetics. 2003; 42(8):743-53. doi: 10.2165/00003088-200342080-00003. [PMID: 12846595]
  • Karin Wåhlander, Maria Eriksson-Lepkowska, Lars Frison, Gunnar Fager, Ulf G Eriksson. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clinical pharmacokinetics. 2003; 42(8):755-64. doi: 10.2165/00003088-200342080-00004. [PMID: 12846596]
  • Troy C Sarich, Renli Teng, Gary R Peters, Maria Wollbratt, Robert Homolka, Mia Svensson, Ulf G Eriksson. No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran. Clinical pharmacokinetics. 2003; 42(5):485-92. doi: 10.2165/00003088-200342050-00006. [PMID: 12739986]
  • Linda C Johansson, Lars Frison, Ulrika Logren, Gunnar Fager, David Gustafsson, Ulf G Eriksson. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clinical pharmacokinetics. 2003; 42(4):381-92. doi: 10.2165/00003088-200342040-00006. [PMID: 12648028]
  • Eva Bredberg, Tommy B Andersson, Lars Frison, Annelie Thuresson, Susanne Johansson, Maria Eriksson-Lepkowska, Marita Larsson, Ulf G Eriksson. Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions. Clinical pharmacokinetics. 2003; 42(8):765-77. doi: 10.2165/00003088-200342080-00005. [PMID: 12846597]
  • Tivadar Fenyvesi, Ingrid Jörg, Christel Weiss, Job Harenberg. Effects of lepirudin, argatroban and melagatran and additional influence of phenprocoumon on ecarin clotting time. Thrombosis research. 2003; 111(1-2):89-94. doi: 10.1016/j.thromres.2003.08.013. [PMID: 14644085]
  • Karin Wåhlander, Leif Lapidus, Carl-Gustav Olsson, Anneli Thuresson, Ulf G Eriksson, Göran Larson, Henry Eriksson. Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. Thrombosis research. 2002 Aug; 107(3-4):93-9. doi: 10.1016/s0049-3848(02)00259-1. [PMID: 12431473]
  • Tivadar Fenyvesi, Ingrid Jörg, Job Harenberg. Monitoring of anticoagulant effects of direct thrombin inhibitors. Seminars in thrombosis and hemostasis. 2002 Aug; 28(4):361-8. doi: 10.1055/s-2002-34305. [PMID: 12244483]
  • T Fenyvesi, I Jörg, J Harenberg. Effect of phenprocoumon on monitoring of lepirudin, argatroban, melagatran and unfractionated heparin with the PiCT method. Pathophysiology of haemostasis and thrombosis. 2002 Jul; 32(4):174-9. doi: 10.1159/000070423. [PMID: 12759518]
  • Bengt I Eriksson, Ann-Christin Arfwidsson, Lars Frison, Ulf G Eriksson, Anders Bylock, Peter Kälebo, Gunnar Fager, David Gustafsson. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery. Thrombosis and haemostasis. 2002 Feb; 87(2):231-7. doi: NULL. [PMID: 11858482]
  • Marita Larsson, Ulrika Logren, Martin Ahnoff, Bo Lindmark, Peter Abrahamsson, Henrik Svennberg, Bengt-Arne Persson. Determination of melagatran, a novel, direct thrombin inhibitor, in human plasma and urine by liquid chromatography-mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2002 Jan; 766(1):47-55. doi: 10.1016/s0378-4347(01)00429-7. [PMID: 11820295]
  • C Mattsson, A Menschiek-Lundin, K Wåhlander, T L Lindahl. Effect of melagatran on prothrombin time assays depends on the sensitivity of the thromboplastin and the final dilution of the plasma sample. Thrombosis and haemostasis. 2001 Aug; 86(2):611-5. doi: 10.1055/s-0037-1616094. [PMID: 11522011]
  • M Elg, S Carlsson, D Gustafsson. Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits. Thrombosis research. 2001 Feb; 101(3):159-70. doi: 10.1016/s0049-3848(00)00398-4. [PMID: 11228339]
  • D Gustafsson, J Nyström, S Carlsson, U Bredberg, U Eriksson, E Gyzander, M Elg, T Antonsson, K Hoffmann, A Ungell, H Sörensen, S Någård, A Abrahamsson, R Bylund. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thrombosis research. 2001 Feb; 101(3):171-81. doi: 10.1016/s0049-3848(00)00399-6. [PMID: 11228340]
  • M Eriksson, S Basu, A Larsson, C Mattsson, O Eriksson, R Kiiski, A Nordgren. Effects of melagatran, a novel direct thrombin inhibitor, during experimental septic shock. Expert opinion on investigational drugs. 2000 May; 9(5):1129-37. doi: 10.1517/13543784.9.5.1129. [PMID: 11060733]
  • M Eriksson, T Saldeen, C Mattsson, A Larsson. Effects of melagatran, an inhibitor of thrombin, on fibrin deposits, haemodynamics, and platelet count in endotoxaemic pigs. Acta anaesthesiologica Scandinavica. 2000 Jan; 44(1):24-31. doi: 10.1034/j.1399-6576.2000.440105.x. [PMID: 10669267]
  • H Eriksson, U G Eriksson, L Frison, P O Hansson, P Held, M Holmström, A Hägg, T Jonsson, L Lapidus, B Leijd, D Stockelberg, U Säfwenberg, A Taghavi, M Thorsén. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. Thrombosis and haemostasis. 1999 Mar; 81(3):358-63. doi: 10.1055/s-0037-1614477. [PMID: 10102460]
  • M Eriksson, A Larsson, T Saldeen, C Mattsson. Melagatran, a low molecular weight thrombin inhibitor, counteracts endotoxin-induced haemodynamic and renal dysfunctions in the pig. Thrombosis and haemostasis. 1998 Dec; 80(6):1022-6. doi: 10.1055/s-0037-1615405. [PMID: 9869178]
  • J L Mehta, L Chen, W W Nichols, C Mattsson, D Gustafsson, T G Saldeen. Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery. Journal of cardiovascular pharmacology. 1998 Mar; 31(3):345-51. doi: 10.1097/00005344-199803000-00003. [PMID: 9514177]
  • D Gustafsson, T Antonsson, R Bylund, U Eriksson, E Gyzander, I Nilsson, M Elg, C Mattsson, J Deinum, S Pehrsson, O Karlsson, A Nilsson, H Sörensen. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thrombosis and haemostasis. 1998 Jan; 79(1):110-8. doi: 10.1055/s-0037-1614245. [PMID: 9459334]
  • M Elg, D Gustafsson, J Deinum. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis. Thrombosis and haemostasis. 1997 Oct; 78(4):1286-92. doi: 10.1055/s-0038-1657729. [PMID: 9364999]